Beijing Beilu Pharmaceutical Co., Ltd. (SHE:300016)
China · Delayed Price · Currency is CNY 10.30
+0.27 (2.69%)
Feb 4, 2026, 11:44 AM CST
SHE:300016 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,116 | 973.49 | 884.3 | 761.45 | 856.85 | 826.95 |
Other Revenue | 10.07 | 10.07 | 6.42 | 4.43 | 3.06 | 0.39 |
| 1,127 | 983.55 | 890.72 | 765.88 | 859.91 | 827.34 | |
Revenue Growth (YoY) | 16.06% | 10.42% | 16.30% | -10.93% | 3.94% | 1.00% |
Cost of Revenue | 632.35 | 524.59 | 485.37 | 365.47 | 327.99 | 280.52 |
Gross Profit | 494.17 | 458.97 | 405.35 | 400.41 | 531.92 | 546.82 |
Selling, General & Admin | 350.42 | 332.21 | 298.78 | 296.25 | 363.6 | 345.85 |
Research & Development | 80.03 | 69.24 | 122.33 | 99.01 | 47.23 | 51.72 |
Other Operating Expenses | 5.98 | 5.22 | 5.6 | 11.16 | -5 | 11.61 |
Operating Expenses | 439.66 | 405.73 | 430.35 | 405.53 | 404.37 | 409.49 |
Operating Income | 54.51 | 53.24 | -25 | -5.12 | 127.55 | 137.33 |
Interest Expense | -51.18 | -58.01 | -53.14 | -47.64 | -44.19 | -4.84 |
Interest & Investment Income | 12.42 | 12.73 | 17.81 | 8.48 | 26.32 | 16.61 |
Currency Exchange Gain (Loss) | 1.18 | 1.18 | -2.76 | -1.14 | 5.31 | 0.97 |
Other Non Operating Income (Expenses) | -1.1 | -0.74 | -0.38 | -1.79 | -1.84 | -1.41 |
EBT Excluding Unusual Items | 15.83 | 8.4 | -63.47 | -47.21 | 113.15 | 148.66 |
Impairment of Goodwill | - | - | -31.82 | - | - | - |
Gain (Loss) on Sale of Investments | 6.75 | -11.95 | -13.96 | 20.54 | 13.9 | 19.41 |
Gain (Loss) on Sale of Assets | -1.52 | 0.12 | 0.89 | 0.1 | 0.13 | - |
Asset Writedown | -2.25 | -1.14 | -1.24 | -0.36 | -0.76 | -4.34 |
Other Unusual Items | 3.32 | 3.78 | 8.43 | 12.17 | -4.06 | 10.11 |
Pretax Income | 22.13 | -0.78 | -101.15 | -14.76 | 122.36 | 173.84 |
Income Tax Expense | 1.4 | -1.05 | -17.95 | -10.21 | 12.06 | 19.84 |
Earnings From Continuing Operations | 20.73 | 0.27 | -83.2 | -4.55 | 110.29 | 154 |
Minority Interest in Earnings | 12.7 | 13.38 | 11.44 | 15.83 | 15.22 | 20.71 |
Net Income | 33.43 | 13.65 | -71.76 | 11.28 | 125.51 | 174.7 |
Net Income to Common | 33.43 | 13.65 | -71.76 | 11.28 | 125.51 | 174.7 |
Net Income Growth | - | - | - | -91.01% | -28.16% | -48.98% |
Shares Outstanding (Basic) | 468 | 455 | 478 | 564 | 483 | 485 |
Shares Outstanding (Diluted) | 468 | 455 | 478 | 564 | 483 | 485 |
Shares Change (YoY) | -3.04% | -4.88% | -15.21% | 16.87% | -0.52% | -0.80% |
EPS (Basic) | 0.07 | 0.03 | -0.15 | 0.02 | 0.26 | 0.36 |
EPS (Diluted) | 0.07 | 0.03 | -0.15 | 0.02 | 0.26 | 0.36 |
EPS Growth | - | - | - | -92.31% | -27.78% | -48.57% |
Free Cash Flow | -40.68 | 61.63 | -86.15 | 25.03 | -39.03 | 3.9 |
Free Cash Flow Per Share | -0.09 | 0.14 | -0.18 | 0.04 | -0.08 | 0.01 |
Dividend Per Share | 0.050 | 0.050 | - | 0.070 | 0.070 | 0.060 |
Dividend Growth | - | - | - | - | 16.67% | -14.29% |
Gross Margin | 43.87% | 46.66% | 45.51% | 52.28% | 61.86% | 66.09% |
Operating Margin | 4.84% | 5.41% | -2.81% | -0.67% | 14.83% | 16.60% |
Profit Margin | 2.97% | 1.39% | -8.06% | 1.47% | 14.60% | 21.12% |
Free Cash Flow Margin | -3.61% | 6.27% | -9.67% | 3.27% | -4.54% | 0.47% |
EBITDA | 151.42 | 143.45 | 56.28 | 69.81 | 190.24 | 180.04 |
EBITDA Margin | 13.44% | 14.59% | 6.32% | 9.11% | 22.12% | 21.76% |
D&A For EBITDA | 96.91 | 90.21 | 81.28 | 74.93 | 62.7 | 42.7 |
EBIT | 54.51 | 53.24 | -25 | -5.12 | 127.55 | 137.33 |
EBIT Margin | 4.84% | 5.41% | -2.81% | -0.67% | 14.83% | 16.60% |
Effective Tax Rate | 6.31% | - | - | - | 9.86% | 11.41% |
Revenue as Reported | 1,127 | 983.55 | 890.72 | 765.88 | 859.91 | 827.34 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.